Search Result

Results for "

MCF7/HCT116

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) Aminopeptidase (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (20) Autophagy (1) Bacterial (2) Bcl-2 Family (3) c-Kit (1) Carbonic Anhydrase (2) Casein Kinase (2) Caspase (3) CDK (8) Checkpoint Kinase (Chk) (1) COX (1) Dihydrofolate reductase (DHFR) (1) DNA Methyltransferase (1) DNA/RNA Synthesis (3) Drug Derivative (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (12) Farnesyl Transferase (1) Ferroptosis (1) Glutaminase (1) Glutathione Peroxidase (1) HDAC (3) HSP (2) MDM-2/p53 (2) Microtubule/Tubulin (4) Mitochondrial Metabolism (1) Na+/K+ ATPase (1) PARP (1) Phosphodiesterase (PDE) (1) PI3K (1) Pim (4) PPAR (1) Quinone Reductase (1) Raf (2) Reactive Oxygen Species (ROS) (5) SARS-CoV (1) Src (1) SRPK (1) STAT (1) Topoisomerase (6) Trk Receptor (1) VEGFR (3)
By Research Areas:	Cancer (66) Infection (6) Inflammation/Immunology (2) Neurological Disease (1)

By Targets:

ACSL Family (1)

Aminopeptidase (1)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (20)

Autophagy (1)

Bacterial (2)

Bcl-2 Family (3)

c-Kit (1)

Carbonic Anhydrase (2)

Casein Kinase (2)

Caspase (3)

CDK (8)

Checkpoint Kinase (Chk) (1)

COX (1)

Dihydrofolate reductase (DHFR) (1)

DNA Methyltransferase (1)

DNA/RNA Synthesis (3)

Drug Derivative (2)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (12)

Farnesyl Transferase (1)

Ferroptosis (1)

Glutaminase (1)

Glutathione Peroxidase (1)

HDAC (3)

HSP (2)

MDM-2/p53 (2)

Microtubule/Tubulin (4)

Mitochondrial Metabolism (1)

Na+/K+ ATPase (1)

PARP (1)

Phosphodiesterase (PDE) (1)

PI3K (1)

Pim (4)

PPAR (1)

Quinone Reductase (1)

Raf (2)

Reactive Oxygen Species (ROS) (5)

SARS-CoV (1)

Src (1)

SRPK (1)

STAT (1)

Topoisomerase (6)

Trk Receptor (1)

VEGFR (3)

By Research Areas:

Cancer (66)

Infection (6)

Inflammation/Immunology (2)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18351

Indotecan LMP-400; NSC-724998	Topoisomerase	Infection Cancer
Indotecan (LMP-400), an indenoisoquinoline derivative, is a potent Topoisomerase I inhibitor, with IC₅₀s of 300, 1200, 560 nM for P388, HCT116, MCF-7 cell lines, respectively. Indotecan prevents the relaxation of supercoiled DNA and can be used for the research of visceral leishmaniasis .

HY-110088

SCH529074 3 Publications Verification	MDM-2/p53	Cancer
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a K_i of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .

HY-15587

L82	DNA/RNA Synthesis	Cancer
L82 is a selective and uncompetitive DNA ligase 1 (DNA Lig1) inhibitor (hLig1 IC₅₀=12 μM). L82 shows anti-proliferative activity to breast cancer cells .

HY-170935

SRSF1-IN-1	SRPK PARP Caspase Apoptosis Autophagy	Cancer
SRSF1-IN-1 is a SRSF1 inhibitor. SRSF1-IN-1 inhibits SRSF1 expression, thereby modulating the splicing of Bcl-x pre-mRNA. SRSF1-IN-1 inhibits the proliferation of various cancer cells. SRSF1-IN-1 induces apoptosis in gastric cancer cells, reduces Bcl-xl expression, and upregulates cleaved PARP and caspase 3. SRSF1-IN-1 induces autophagy and promotes cell death. SRSF1-IN-1 exhibits anti-tumor activity in a mouse gastric cancer xenograft model. SRSF1-IN-1 can be used for the research of various cancers including liver cancer, gastric cancer, breast cancer, colon cancer, glioma, and melanoma .

HY-18351A

Indotecan hydrochloride LMP-400 hydrochloride; NSC-724998 hydrochloride	Topoisomerase	Infection Cancer
Indotecan hydrochloride, an indenoisoquinoline derivative, is a potent Topoisomerase I inhibitor, with IC₅₀s of 300, 1200, 560 nM for P388, HCT116, MCF-7 cell lines, respectively. Indotecan hydrochloride prevents the relaxation of supercoiled DNA and can be used for the research of visceral leishmaniasis .

HY-139342

CDK7-IN-4	CDK	Cancer
CDK7-IN-4 (compound I) is a potent CDK7 (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner .

HY-146819

CAIX/CAXII-IN-1	Carbonic Anhydrase	Cancer
Compound 9 is the most effective against tumor specific Ca ix/ca XII (ki=29.1 and 8.8 nm), so it is possible to evaluate its cytotoxicity and selectivity to HepG-2, HCT-116 and MCF-7 cancer cell lines in vitro, and its IC₅₀ values to tumor cells are 1.78, 1.94 and 3.07, respectively μ M. It showed that it had obvious cytotoxicity.

HY-156912

Tyrosine kinase-IN-7	EGFR	Cancer
Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC₅₀s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC₅₀s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively .

HY-147920

PIM1-IN-6	Pim	Cancer
PIM1-IN-6 (compound 5h) is a potent PIM-1 inhibitor, with an IC₅₀ of 0.60 μM. PIM1-IN-6 shows the high cytotoxicity activity against HCT-116 and MCF-7 cells, with IC₅₀ values of 1.51 and 15.2 μM, respectively .

HY-156470

Multi-kinase-IN-6	Trk Receptor Anaplastic lymphoma kinase (ALK) c-Kit EGFR Pim Casein Kinase Checkpoint Kinase (Chk) CDK Apoptosis	Cancer
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC₅₀ values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .

HY-147839

Topoisomerase II inhibitor 10	Topoisomerase Apoptosis	Cancer
Topoisomerase II inhibitor 10 (compound 32a) is a potent topoisomerase II inhibitor with an IC₅₀ value of 7.45 μM. Topoisomerase II inhibitor 10 causes cell cycle arrest at G2-M phase and induces apoptosis of HepG-2 cells. Topoisomerase II inhibitor 10 has excellent anti-proliferative activities against HepG-2, MCF-7, and HCT-116 cells .

HY-161687

Cisplatin/Dasatinib prodrug-1	Src	Cancer
Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC₅₀s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .

HY-178112

CDK2-IN-47	CDK Apoptosis	Cancer
CDK2-IN-47 is a potent CDK2 inhibitor with an IC₅₀ of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer .

HY-170910

Hsp90-IN-39	HSP	Cancer
Hsp90-IN-39 (Compound 16t) is a HSP90 inhibitor with notable selectivity for the HSP90α isoform. Hsp90-IN-39 demonstrates significant antiproliferative activity in various cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 holds potential for cancer research .

HY-157419

FL77-24 7-(4-Ethylphenyl)-FL118	Apoptosis	Cancer
FL77-24, a FL118 analog and apoptosis inducer, possesses antitumor activity, with IC₅₀ values of 99.4 nM, 118 nM, <6.4 nM, 28.5 nM and <6.4 nM in HCT116, HepG2, MCF-7, A549 and HeLa cells, respectively. FL77-24 mainly causes cell cycle arrest in S and G2/M phases .

HY-N2150

Psammaplin A	HDAC DNA Methyltransferase DNA/RNA Synthesis Bacterial Aminopeptidase Farnesyl Transferase PPAR Apoptosis	Infection Inflammation/Immunology Cancer
Psammaplin A is a marine metabolite. Psammaplin A is a selective HDAC1 (IC₅₀: 45 nM), DNA methyltransferases (IC₅₀: 18.6 nM) and aminopeptidase N (APN) (IC₅₀: 18 μM) inhibitor. Psammaplin A also inhibits DNA topoisomerase and farnesyl protein transferase. Psammaplin A is a PPARγ activator and induces apoptosis. Psammaplin A has antitumor and anti-inflammatory activities. Psammaplin A has antibacterial activity against Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Psammaplin A inhibits angiogenesis .

HY-174404

Topoisomerase II inhibitor 23	Topoisomerase Apoptosis Bcl-2 Family	Cancer
Topoisomerase II inhibitor 23 is a potent topoisomerase II inhibitor (IC₅₀= 0.94 μM). Topoisomerase II inhibitor 23 shows high selectivity and exceptional cytotoxic activity in MCF-7, HepG2, and HCT116 cells. Topoisomerase II inhibitor 23 induces cell cycle arrest at the G1 phase, leading to inhibition of cell proliferation. Topoisomerase II inhibitor 2 induces apoptosis by up-regulating the pro-apoptotic Bax level and down-regulating the anti-apoptotic Bcl-2 level.

HY-172097

HL22	Drug Derivative	Cancer
HL22 is a harmaline derivative. HL22 significantly inhibits HCT116, MGC803 and MCF7 cancer cell lines, and inhibits MGC803 cell migration and monoclonal formation. The anti-cancer mechanism of HL22 is related to a variety of metabolic pathways and can be used in the study of cancer .

HY-170895

Hsp90-IN-38	HSP Na+/K+ ATPase	Cancer
Hsp90-IN-38 (compound 20m) is a HSP90 (heat shock protein) inhibitor. Hsp90-IN-38 exhibits strong HSP90 binding affinity with a K_d of 87 nM. Hsp90-IN-38 inhibits ATPase with an IC₅₀ of 0.13 μM. Hsp90-IN-38 inhibits HCT116, MCF-7, SKBr3, K562 and A549 cells with IC₅₀s of 0.187, 0.072, 0.105, 0.403 and 031 μM, respectively .

HY-113796

Kopsoffinol	Others	Cancer
Kopsoffinol, a bisindole alkaloid, shows in vitro growth inhibitory activity against human PC-3, HCT-116, MCF-7, and A549 cells and moderate effects in reversing multidrug-resistance in vincristine-resistant human KB cells .

HY-175698

Ferroptosis inducer-9	ACSL Family Ferroptosis Microtubule/Tubulin COX Glutathione Peroxidase	Cancer
Ferroptosis inducer-9 is a ferroptosis inducer and colchicine site tubulin polymerization inhibitor. Ferroptosis inducer-9 inhibits MCF-7 cell growth with an IC₅₀ of 14 nM and inhibits [ ³H]colchicine binding. Ferroptosis inducer-9 reduces expression of GPX4 and FTH, increases COX2 and ACSL4, lowers GSH, NADP+, and NADPH levels, increases LPO, MDA, and Fe(II) levels, and decreases SOD concentrations. Ferroptosis inducer-9 demonstrates significant anti-tumor efficacy in HCT116 CRC xenograft model. Ferroptosis inducer-9 can be used for the study of triple negative breast cancer (TNBC) and colorectal cancer (CRC) .

HY-156444

HDAC1/CDK7-IN-1	HDAC CDK Apoptosis	Cancer
HDAC1/CDK7-IN-1 (compound 8e) is a dual *CDK7* and HDAC1 inhibitor with IC₅₀s of 893 nM and 248 nM, respectively. HDAC1/CDK7-IN-1 inhibits the growth cells of MDA-MB-231, MCF-7, A549, and HCT-116 cancer cells. HDAC1/CDK7-IN-1 induces cell cycle arrest and apoptosis in HCT-116 cells, as well as hindered the migration of HCT-116 cells .

HY-157402

Topoisomerase II/EGFR-IN-1	Topoisomerase EGFR	Cancer
Topoisomerase II/EGFR-IN-1 is topoisomerase II/EGFR dual inhibitor. Topoisomerase II/EGFR-IN-1 has superior cytotoxic activity to MCF-7, A549 and HCT-116 cell lines, displays strong apoptotic activity and can be used for the research of cancer .

HY-147921

PIM1-IN-7	Pim	Cancer
PIM1-IN-7 (compound 6c) is a potent PIM-1 inhibitor, with an IC₅₀ of 0.67 μM. PIM1-IN-7 shows the high cytotoxicity activity against HCT-116 and MCF-7 cells, with IC₅₀ values of 42.9 and 7.68 μM, respectively .

HY-149995

Pim-1 kinase inhibitor 5	Pim	Cancer
Pim-1 kinase inhibitor 5 (Compound 4c) is a Pim-1 kinase inhibitor (IC₅₀: 0.61 μM). Pim-1 kinase inhibitor 5 shows cytotoxicity against cancer cells, with IC₅₀s of 6.95-20.19 μM for HepG2, MCF-7, PC3, and HCT-116 cells .

HY-164619

CDK9-IN-34	CDK SARS-CoV	Infection Cancer
CDK9-IN-34 (Compound 1b) is an inhibitor for CDK9 with an IC₅₀ of 0.25 μM. CDK9-IN-34 exhibits cytotoxicity to cancer cell HCT116, MCF7 and K652 with IC₅₀s of 1.43, 3.01 and 50.27 μM, respectively. CDK9-IN-34 exhibits antiviral activity against coronavirus 229E with an IC₅₀ of 145.92 μM .

HY-158371

HDAC/CK2-IN-1	HDAC Casein Kinase	Cancer
HDAC/CK2-IN-1 (compound 38) is a HDAC1 (IC₅₀ = 1.46 μM), HDAC6 (IC₅₀ = 0.66 μM), and CK2 (IC₅₀ = 3.67 μM) inhibitor. HDAC/CK2-IN-1 exhibits promising antproliferative activity against Jurkat, MCF-7, HCT-116, and HL-60 cell lines .

HY-161641

Tubulin polymerization-IN-62	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-62 (Compound 14b) is an inhibitor for microtubule polymerization (IC₅₀ is 7.5 μM) and a degrader for α- and β-tubulin. Tubulin polymerization-IN-62 inhibits proliferation of cancer cells MCF-7, A549 and HCT-116, with IC₅₀ of 32, 60 and 29 nM, respectively. Tubulin polymerization-IN-62 arrests the cell cycle at G2/M phase, inhibits the migration of MCF-7. Tubulin polymerization-IN-62 exhibits antitumor efficacy with a tumor growth inhibition rate (TGI) of 74.27% in 4T1 homograft mouse model .

HY-147853

B-Raf IN 8	Raf	Cancer
B-Raf IN 8 (compound 7g) is a potent B-Raf inhibitor, with an IC₅₀ of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC₅₀ values of 9.78, 13.78, 18.52 and 29.85 µM .

HY-147852

B-Raf IN 7	Raf	Cancer
B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC₅₀ of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC₅₀ values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .

HY-162670

Anticancer agent 238	CDK	Cancer
Anticancer agent 238 (compound 5) is an anticancer agent with a notably strong binding affinity towards the CDK-5 enzyme. Anticancer agent 238 shows a strong efficacy agains HCT116 and MCF7 cells, with IC₅₀ values of 13.46 µM and 16.43 µM, respectively .

HY-167694

Antiproliferative agent-62	Quinone Reductase	Cancer
Antiproliferative agent-62 (compound 5) is a functionalized benzylidene-indolin-2-one with notable antiproliferative activity and NQO1 activity induciton funciton, particularly in inducing NQO1 expression in murine Hepa1c1c7 cells and demonstrating effectiveness against human cancer cell lines, including MCF-7 and HCT116.

HY-163615

Antimicrobial agent-32	Bacterial	Infection
Antimicrobial agent-32 (Compound 4g) is an antimicrobial agent that exhibits significant activity against various bacteria, including Staphylococcus aureus, Bacillus subtilis, Bacillus cereus (MIC=1000 µg/mL), Klebsiella pneumonia, and Staphylococcus aureus (MRSA) (MIC=500 µg/mL), as well as Escherichia coli (MIC=250 µg/mL). Additionally, Antimicrobial agent-32 inhibits the proliferation of MCF-7, HCT-116, and HepG-2 cells, demonstrating anticancer activity .

HY-146103

Antiproliferative agent-7	Apoptosis Reactive Oxygen Species (ROS)	Cancer
Antiproliferative agent-7 (compound 8f) is a potent anti-proliferative agent. Antiproliferative agent-7 has antiproliferative activity against cancer cell lines MCF-7, MDA-MB-231, HCT-116 and FR-2 with IC₅₀s of 3.5 μM, 15.54 μM, 30.43 μM and 34.8 μM, respectively. Antiproliferative agent-7 can increase ROS production and induce apoptosis .

HY-150968

Antiproliferative agent-11	Apoptosis	Cancer
Antiproliferative agent-11 (compound 7) is an antiproliferative and selective Ruthenium(II)-Tris-pyrazolylmethane complex. Antiproliferative agent-11 shows antiproliferative activity towards MCF-7, HeLa, 518A2, HCT116 and RD with IC₅₀s of 6, 10, 6.8, 6.7 and 6 μM, respectively. Antiproliferative agent-11 can be used for the research of cancer .

HY-146454

Antiproliferative agent-6	DNA/RNA Synthesis	Cancer
Antiproliferative agent-6 (compound 8a) is a potent antitumor agent. Antiproliferative agent-6 has antiproliferative activity against cancer cell lines HCT116, MCF-7, H460 and non-tumor aneuploid immortal keratinocyte HaCaT cells with GI₅₀s of 0.5 μM, 2 μM, 0.7 μM and 3.5 μM, respectively .

HY-175174

Antiproliferative agent-73	Glutaminase	Cancer
Antiproliferative agent-73 (Compound 7) is an antiproliferative agent. Antiproliferative agent-73 significantly inhibits proliferation of human cancer cells with excellent cytotoxicity. Antiproliferative agent-73 has potent anticancer activity with IC₅₀s of 15.20, 18.18, 20.20 and 13.23 μM for HepG2, MCF-7, HCT-116 and WI38 cells, respectively. Antiproliferative agent-73 can be used for cancers research, such as breast, colorectal and liver cancer .

HY-175779

TDP1-IN-4	Phosphodiesterase (PDE)	Cancer
TDP1-IN-4 (Compound 33) is a Tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with an IC₅₀ of 0.90  μM. TDP1-IN-4 has a strong synergistic effect with Camptothecin (HY-16560) in SK-Mel-2 cells, but not in cancer cells (A549, HCT-116 and MCF-7 cells) and non-cancerous Ges-1 cells. TDP1-IN-4 can be used for cancer chemotherapy and radiotherapy research .

HY-155177

CDK9-IN-27	CDK	Cancer
CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC₅₀s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC₅₀s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research .

HY-155118

EGFR-IN-81	EGFR	Cancer
EGFR-IN-81 (Compound 10i) is an EGFR inhibitor. EGFR-IN-81 inhibits EGFR WT and L858R/T790M with IC₅₀s 4.38 nM and 5.69 nM. EGFR-IN-81 has cytotoxic activity against MCF-7 and HCT116 cells with of 2.07 μM and 6.72 μM respectively .

HY-161324

Tubulin degrader 1	Microtubule/Tubulin	Cancer
Tubulin degrader 1 (Compound 5i) is a BML284 (HY-19987) derivative that is an orally active colchicine-site noncovalent tubulin degradation agent with IC₅₀ values ranging from 0.02 to 0.05 μM against the five tumor cell lines (Hela, HCT116, MCF-7, K562 and Molm-13). Tubulin degrader 1 has antiproliferative activity that effectively suppressed tumor growth .

HY-163678

Pomalidomide-CO-C7-NH-CO-C3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-CO-C7-NH-CO-C3-COOH is a conjugate of a ligand for E3 ligase and a linker. Pomalidomide-CO-C7-NH-CO-C3-COOH can be used for synthesis of PROTAC degrader ARM165 (HY-163677) .

HY-156018

PI3Kα-IN-13	PI3K	Cancer
PI3Kα-IN-13 (Compound 18a) is a PI3Kα inhibitor (IC₅₀: 2.5 nM). PI3Kα-IN-13 induces tumor cell apoptosis. PI3Kα-IN-13 inhibits cancer cell proliferation with IC₅₀s of 0.75 μM (MCF-7), 3.79 μM (HCT-116), 13.71 μM (MDA-MB-231), 9.85 μM (SW620), respectively. PI3Kα-IN-13 inhibits tumor cell colony formation, migration and invasion .

HY-173492

EGFR-IN-156	EGFR Apoptosis	Cancer
EGFR-IN-156 (Compound 7f) is an EGFR inhibitor that also has inhibitory activity against mutations EGFRL858R and EGFRT790M (IC₅₀ values are 0.186, 0.131, and 0.107 μM, respectively). EGFR-IN-156 has significant anticancer activity against human cancer cell lines HepG-29 (liver cancer), MCF-7 (breast cancer), and HCT-116 (colon cancer) (IC₅₀ values are 1.67, 5.32, and 6.56 μM, respectively). EGFR-IN-156 inhibits cancer cell proliferation by inducing cell cycle arrest at the G/G1 phase and triggering apoptosis. EGFR-IN-156 shows promise in EGFR-related cancers .

HY-186161

Antiproliferative agent-77	Others	Cancer
Antiproliferative agent-77 is an anticancer cell proliferation agent that exerts significant antiproliferative effects on HCT116, HepG2, H1299 and MCF-7 .

HY-159122

CA IX-IN-2	Carbonic Anhydrase Reactive Oxygen Species (ROS) Apoptosis	Cancer
CA IX-IN-2 (Compound 9o) is an inhibitor for carbonic anhydrase (CA), that inhibits CA IX, CA XII and CA II with an IC₅₀ of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC₅₀s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .

HY-168435

VEGFR-2-IN-63	VEGFR	Cancer
VEGFR-2-IN-63 (Compound 12b) is the inhibitor for VEGFR2 that inhibits 87.2% VEGFR-2 at 10 μM. VEGFR-2-IN-63 exhibits antiproliferative activity in multiple cancer cell, IC₅₀s for HCT116, MCF7 and PaCa2 is 6.5 μM, 2.1 μM and 4.1 μM, respectively .

HY-161786

Bcl-2-IN-20	Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS)	Cancer
Bcl-2-IN-20 (Compound 81) is an inhibitor for Bcl-2 with IC₅₀ <10 μM (79.1% inhibition at 9 μM). Bcl-2-IN-20 exhibits cytotoxicity in SK-MEL-28 (IC₅₀>10 μM), A549 (IC₅₀=6.1 μM), HepG2 (IC₅₀>10 μM), MCF-7 (IC₅₀=8.9 μM), HCT116 (IC₅₀>10 μM) and HEK-293 (IC₅₀=14.1 μM). Bcl-2-IN-20 promotes the ROS production, induces apoptosis and DNA damage .

HY-169096

DPP-21	Microtubule/Tubulin Apoptosis	Cancer
DPP-21 is an inhibitor of tubulin polymerization (IC₅₀: 2.4 μM). DPP-21 shows anti-proliferative activity against cancer cell lines, with IC₅₀s of 0.38 nM (HCT116), 11.69 nM (B16), 5.37 nM (HeLa), 9.53 nM (MCF7), 8.94 nM (H23) and 9.37 nM (HepG2) respectively. DPP-21 arrests the cell cycle in the G2/M phase of mitosis, subsequently inducing tumor cell apoptosis (decreases Bcl-2 but upregulates the pro-apoptotic protein Bax) .

HY-155239

VEGFR-2-IN-35	VEGFR	Cancer
VEGFR-2-IN-35 (compound 7) is a potent VEGFR-2 inhibitor with IC₅₀=37 nM. VEGFR-2-IN-35 inhibits MCF-7 and HCT 116 cancer cells with IC₅₀ values of 10.56 and 7.07 μM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting MDM2 and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks